Vertex, Arbor team up to develop ex vivo engineered cell therapies
Vertex will use Arbor’s CRISPR gene-editing technology in developing novel cell therapies for the treatment of serious diseases
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 Aug 21
Vertex will use Arbor’s CRISPR gene-editing technology in developing novel cell therapies for the treatment of serious diseases
24 Aug 21
Comirnaty is said to be the first Covid-19 vaccine to receive full FDA approval and is indicated to…
24 Aug 21
The acquisition is expected to benefit Pfizer with Trillium’s next-generation, investigational immuno-therapeutics for haematological malignancies
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Aug 21
Detecting biofilms is a real problem for wound care, but there are new diagnostic tools available that practitioners…
23 Aug 21
Zydus claims that its ZyCoV-D is the world's first plasmid DNA vaccine for Covid-19, with well-established safety, efficacy…
20 Aug 21
A focus on challenges presented by the pandemic and how this will create a more sustainable and efficient…
20 Aug 21
The EC approval for Abecma is based KarMMa trial, which showed rapid, deep and durable responses with a…
20 Aug 21
The expansion is said to increase the company’s capability to manufacture complex APIs and generate new jobs at…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
19 Aug 21
The US FDA approved Jardiance based on results from the Phase 3 EMPEROR-Reduced trial, in which the drug…
18 Aug 21
Cosentyx was previously approved in China for the treatment of moderate-to-severe plaque psoriasis and ankylosing spondylitis in adults